regulatory
confidence high
sentiment negative
materiality 0.70
Iterum Therapeutics receives Nasdaq delisting notice for MVLS below $35M
Iterum Therapeutics plc
- Nasdaq notified Iterum on Dec 11, 2025 that MVLS <$35M for 30 consecutive business days; given 180 days until June 9, 2026 to regain compliance.
- Company also remains out of compliance with $1.00 minimum bid price rule since August 2025, with compliance period ending Feb 23, 2026.
- Failure to cure either deficiency could lead to delisting; company may appeal but no assurance of success.
- Notice has no immediate effect on listing; common stock continues trading on Nasdaq.